MGX · Metagenomi, Inc. Common Stock

Metagenomi Therapeutics reported its first quarter 2026 financial results, highlighting a cash position of $140.2 million as of March 31, 2026, which management expects to fund operations through the fourth quarter of 2027. The company's lead program, MGX-001 for hemophilia A, remains on track for regulatory submission, including an IND, in the fourth quarter of 2026, with first-in-human studies anticipated in 2027. Research and development expenses decreased to $19.3 million from $25.1 million in the same quarter last year, while general and administrative expenses were relatively flat at $6.5 million. Collaboration revenue declined to $1.2 million from $4.1 million. Net loss improved to $23.1 million, or $0.61 per share, compared to $25.0 million, or $0.68 per share, in the prior year period. The company also highlighted a publication in Nature Structural & Molecular Biology detailing its compact CRISPR nuclease MG119-28, which demonstrated superior editing efficiency. Management commentary emphasized confidence in the MGX-001 program and the potential for one-time curative treatments. The company also disclosed the appointment of Kapil Saxena, MD to lead clinical development for MGX-001. The corporate presentation furnished as Exhibit 99.2 provides additional details on the platform and pipeline.